, Singapore

Singapore becomes home-base of biomedical firms

In 2009 biomedical sciences investments amounted to S$1.2 billion in total fixed asset investment and S$700 million in total business spending.

According to the Singapore Economic Development Board (EDB), "In 2009, global biomedical sciences companies have located strategic functions in Singapore that include regional headquarters (e.g. Medtronic, Quintiles, Takeda), first-in-Asia and global manufacturing facilities (e.g. GlaxoSmithKline, Illumina, Lonza, Medtronic, ResMed, Roche) and R&D bases in Asia (e.g. Abbott, 3M, Merck, Roche, Inviragen, FORMA)."

Singapore's biomedical manufacturing output in 2009 grew steadily to about S$21 billion and employed more than 13,000 people. Current investments, when fully implemented, will create more than 1,600 jobs for professionals, managers, engineers, research scientists and engineers, and skilled workers.

Mr Julian Ho, EDB Assistant Managing Director, said, "The global biomedical sciences industry is confronted with the need to improve R&D productivity. At the same time, they need to navigate Asia’s complexities and diversity to effectively tap into the region’s fast-growing markets. As Asia’s leading bio-cluster, Singapore is well-positioned to help biomedical sciences companies accelerate their innovation and capitalise on Asia’s growth story."

Join Singapore Business Review community
Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.